Healthpeak Properties, Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 748 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Company identity: ticker is DOC (Healthpeak Properties, Inc., CIK 0000765880). The ticker changed from PEAK to DOC in 2024 upon completion of the merger with Physicians Realty Trust, which itself had previously traded as NYSE: DOC; Physicians Realty Trust is now a wholly owned, consolidated subsidiary and is EXCLUDED here as a holding per the brief's rule on wholly owned operating subsidiaries.
• Holdings side, headline finding: on 20 Mar 2026 Healthpeak spun off its senior housing portfolio into Janus Living, Inc. (NYSE: JAN) via an IPO, retaining 138,816,246 Class A-1 (tradable common) shares plus 75,917,780 Janus Living OP common units and an equal number of non-economic, voting-only Class A-2 shares, for 73.6% combined voting and economic control as of 30 Jun 2026. Because Janus Living is a separately publicly traded company that Healthpeak does not wholly own, this is recorded as a holding (target_ticker JAN) even though it is consolidated in Healthpeak's own financial statements; the OP units and Class A-2 shares are kept out of the 'shares' field per the brief's instruction that a unit-denominated interest is not a common-share count, and the combined percentage and its arithmetic are spelled out in method_note.
• Holdings side, unconsolidated JVs: Healthpeak's 30 Jun 2026 10-Q, Note 7, discloses a table giving BOTH a carrying amount AND an ownership percentage for each of 9 currently held equity-method joint ventures (South San Francisco JVs 70%, Callan Ridge JV 35%, HQ Point Preferred Equity Investment 36%, BX JV I and II 20% each, Lab JV 49%, PMAK JV 12%, Needham Land Parcel JV 38%, Outpatient Medical JV/Suburban Properties 67%, Davis JV 48%), summing to the $526,780 thousand 'Investments in unconsolidated joint ventures' balance on the 30 Jun 2026 balance sheet exactly. Unlike a combined, undisaggregated balance, this table let every JV be sized individually with a filed carrying value rather than null; all pct_of_target values above are written as whole percentages (70, 35, 36, 20, 49, 12, 38, 67, 48), not fractions, and were checked against this file's own method_note prose before reporting. A tenth JV, SWF SH JV, held a $312,709 thousand carrying value at 31 Dec 2025 but is EXCLUDED here: in January 2026 Healthpeak bought out its JV partner's 46.5% interest for $312 million cash, consolidating the 19 senior housing communities, so Healthpeak's carrying value in it was $0 (fully consolidated) at 30 Jun 2026 and it is no longer an equity-method holding.
• DownREITs are treated as CONSOLIDATED, not a holding, per the brief's instruction to decide DownREIT treatment explicitly. At 30 Jun 2026, non-managing (third-party) members held approximately 11 million DownREIT units, convertible into approximately 13 million shares of Healthpeak common stock, across eight limited liability companies for which Healthpeak holds a controlling interest and/or acts as managing member. These units run the OPPOSITE direction from a Healthpeak holding: they are outside parties' claims against Healthpeak's own consolidated subsidiaries (carrying value $307 million, market value $286 million at 30 Jun 2026), not equity Healthpeak owns in others, so they appear in neither the holdings nor the register side of this file. The same logic applies to Healthpeak's own legacy UPREIT OP Units (6 million outstanding, dilutive in Q2 2026 EPS) and to Janus Living's own OP units held by third parties, both outside-party claims rather than Healthpeak holdings.
• Two equity-method-adjacent items were found but could not be sized to a single investee and carry no holdings row, per the brief's rule against assigning a shared balance to one investee: (1) 'Other Equity Investments', $17 million at 30 Jun 2026, limited-partner interests in MULTIPLE unnamed funds making venture-capital investments in early-stage technology, with a further $13 million in unfunded commitments; no individual fund is named or separately valued. (2) an unnamed 'LLC Investment', a limited-partner VIE whose assets are three hospitals plus senior housing real estate, with no ownership percentage or standalone carrying value disclosed (its maximum loss exposure of $32,105 thousand in the 10-Q's VIE table is a COMBINED figure covering both the LLC Investment and the Other Equity Investments together, not disaggregated).
• Register side: swept the Vanguard family (parent CIK 0000102909 filed Form 13F-NT for Q2 2026, a notice carrying no holdings, so the 7 successor entities ARE the position and were summed per the brief's rule), the full Capital Group family (11 CIKs checked: 3 that filed 13F-NT with no holdings at all, Capital Research & Management Co 0000017283, Capital Group Companies Inc 0000732812, Capital Group International Inc 0000949308; and 8 that filed 13F-HR for Q2 2026 and were each checked directly against CUSIP 42250P103 with ZERO matches: Capital World Investors 0001422849, Capital International Investors 0001562230, Capital Research Global Investors 0001422848, Capital Group Investment Management Pte Ltd 0001939970, Capital Group Private Client Services Inc 0001857666, Capital International Inc/CA/ 0000895213, Capital International Ltd/CA/ 0001065350, Capital International Sarl 0001065349), and both T. Rowe Price registrants (Associates 0000080255, which holds a small position included as a row, and Investment Management Inc 0001897612, which holds zero). Capital Group holds NOTHING in Healthpeak as of Q2 2026; recorded as a note per the brief's rule, not a null row.
• Cohen & Steers, a REIT specialist the brief specifically flagged as a risk case for the values-in-thousands convention, was checked and found to hold NOTHING in Healthpeak as of Q2 2026: the filer with holdings, Cohen & Steers, Inc. CIK 0001284812 (Q2 2026 13F-HR, 442 rows), was searched directly for CUSIP 42250P103 and 'HEALTHPEAK' with zero matches; its affiliate Cohen & Steers Capital Management Inc CIK 0000845563 filed a 13F-NT (no holdings) for the same period. Recorded as a note, not a null row.
• Implied per-share price check across every institutional row: Vanguard family, BlackRock, State Street, Fuller & Thaler, Invesco, Principal, BNY Mellon, and T. Rowe Price all cluster at approximately $21.38-$21.40 per share as of 30 Jun 2026; Geode is close at $21.38; JPMorgan is a modest outlier at $21.89. All are consistent enough to confirm every row is the same CUSIP 42250P103 common-stock instrument at the same date, and are plausibly higher than the 19 Aug 2026 close of $20.76 used for market_cap_usd, reflecting about seven weeks of price drift.
• The DEF 14A's 5%-owner table (Vanguard 87,756,738 sh / 16.04%, BlackRock 70,176,646 sh / 10.00%, State Street 41,217,077 sh / 7.53%, as of 3 Mar 2026) could not be exactly reconciled on Vanguard: 87,756,738 shares divided by the 689,527,260 shares outstanding used throughout this file gives 12.72%, not the proxy's stated 16.04%, suggesting the proxy computed its percentage against a different, unstated share base (a known feature of some proxies' beneficial-ownership tables, which can exclude certain share classes or use a stale count). BlackRock and State Street's proxy percentages DO reconcile closely against 689,527,260 shares. Per the brief's preference for a fresh 13F over a proxy figure, this file uses the freshly re-read Q2 2026 13F numbers for all three and records this discrepancy here rather than silently overwriting it.
• Self-gate, computed from this final file on disk, following the chart's own arithmetic (members at full value; here no register row rolls into another, so every row counts at full value; the directors/officers row is an aggregate with no separate member rows, so it also counts at full value): 11 register rows, 362,102,086 total shares (Vanguard family 110,059,303 + BlackRock 70,935,046 + State Street 44,007,417 + JPMorgan 30,192,317 + Fuller & Thaler 29,119,832 + Geode 24,653,617 + Invesco 18,507,997 + Principal Financial 16,760,575 + BNY Mellon 15,234,655 + T. Rowe Price 1,003,467 + directors/officers aggregate 1,627,860), against shares_outstanding 689,527,260 = 52.52% of the company. This sits above the brief's expected 25-45% band but inside the 55% outer bound the chunk prompt allows before requiring a fix; the brief itself flags REITs as heavily index owned, and the implied-price crosscheck above (every row landing within a few cents of $21.40/share) is strong independent evidence that these are correctly-sourced rows for this single CUSIP rather than a double-count or wrong-instrument error.
• Market cap methodology: market_cap_usd is a live intraday/close quote (stockanalysis.com, $20.76, 19 Aug 2026 close) multiplied by the 3 Aug 2026 10-Q cover-page share count (689,527,260); the two dates are about two weeks apart because no single source carries both a current price and a current share count. stockanalysis.com's own displayed market cap ($14.58bn) is close to but not identical to the $14,314,585,918 computed here, likely reflecting a marginally different share count on their end; the computed figure is used as it is directly traceable to the cited sources.